(Bloomberg) -- Genentech Inc., the world's second- largest biotechnology company, is testing a breast-cancer treatment that may add $1.5 billion in annual sales to its Herceptin drug business.
The experimental therapy increased the effectiveness of Herceptin against drug-resistant cancer cells by linking the drug with chemical toxins, according to a study by the South San Francisco, California-based drugmaker. The treatment binds tumor-killing chemicals to Herceptin, causing fewer side effects by attacking cancer cells and mostly leaving normal tissue alone.
Read more at Bloomberg Exclusive News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment